GlassScriptPhysician profile
Fawad Khan
NPI 1699978122
$488,258.29
in general payments reported to CMS, 2019-2025
32 companies · $92K in 2025
The $92K reported for 2025 was more than what 98% of Clinical Neurophysiology providers received nationally (typical 2025 total: $435).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $63K · 2020: $75K · 2021: $75K · 2022: $92K · 2023: $47K · 2024: $44K · 2025: $92K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $103K · Consulting Fee: $49K · Travel and Lodging: $14K · Food and Beverage: $9,361 · Honoraria: $7,650 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $103,469.50 |
| Consulting Fee | $49,092.67 |
| Travel and Lodging | $13,958.83 |
| Food and Beverage | $9,360.62 |
| Honoraria | $7,650.00 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $82,645.82 | 2021-2025 | |
| Amgen INC. | $59,656.75 | 2019-2022 | |
| Lilly USA, LLC | $48,422.93 | 2019-2023 | Emgality, Reyvow, Amyvid |
| Sk Life Science, INC. | $46,395.57 | 2020-2025 | Xcopri |
| Pfizer INC. | $46,153.09 | 2023-2025 | |
| Lundbeck LLC | $39,988.11 | 2020-2025 | Vyepti |
| Allergan, INC. | $34,928.27 | 2019-2022 | |
| Ucb, INC. | $33,949.99 | 2019-2025 | Nayzilam, Fintepla, Briviact |
| Impel Pharmaceuticals INC. | $28,684.35 | 2022-2023 | Trudhesa |
| Teva Pharmaceuticals USA, INC. | $21,107.59 | 2019-2021 | |
| Neurelis, INC. | $16,280.44 | 2020-2025 | Valtoco |
| Immedica Pharma US, INC. | $11,755.82 | 2023 | |
| Eisai INC. | $8,380.55 | 2019-2023 | |
| Livanova USA, INC. | $3,044.37 | 2019-2024 | Vns Therapy Sentiva Model 1000 Generator, Vns Therapy |
| Dixi Medical USA Corp | $1,684.98 | 2022-2023 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuropace, INC. | $1,608.03 | 2022-2025 | |
| Natus Medical Incorporated | $1,000.00 | 2022 | |
| Zimmer Biomet Holdings, INC. | $920.00 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $496.12 | 2022-2025 | Epidiolex |
| Biohaven Pharmaceuticals, INC. | $287.51 | 2021 | |
| Sunovion Pharmaceuticals INC. | $226.94 | 2019-2020 | |
| Greenwich Biosciences, INC. | $157.70 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $143.61 | 2022 | |
| Novartis Pharmaceuticals Corporation | $99.44 | 2020-2021 | |
| Biogen, INC. | $96.90 | 2021 | |
| Merck Sharp & Dohme LLC | $41.70 | 2024-2025 | Bridion |
| Ethicon US, LLC | $38.33 | 2025 | Echelon; Endopath |
| Axsome Therapeutics, INC. | $31.99 | 2025 | Symbravo |
| Sumitomo Pharma America, INC. | $15.71 | 2023 | Aptiom |
| Upsher-Smith Laboratories LLC | $15.68 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fawad Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.